We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Trevena is a biopharmaceutical company focused on the development and commercializ...
Trevena is a biopharmaceutical company focused ...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treat...
Ardelyx is focused on enhancing the way people ...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.